Cellectar Biosciences Inc. Series A Warrants
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cellectar Biosciences Inc. Series A Warrants generated cash of $0, which is more than the previous year. Cash used in financing activities reached the amount of $60,545,751 last year. Net change in cash is therefore $46,550,655.
Cash Flow
| 2011 | -5.97M | 1.28M | 9.51M |
|---|---|---|---|
| 2012 | -5.97M | 1.28M | 9.51M |
| 2013 | -9.15M | 1.85M | 5.04M |
| 2014 | -8.84M | -29.56K | 15.87M |
| 2015 | -8.21M | -58.47K | 2.70M |
| 2016 | -8.28M | -72.25K | 15.94M |
| 2017 | -11.02M | -346.70K | 9.92M |
| 2018 | -11.44M | -329.99K | 15.02M |
| 2019 | -11.69M | -24.54K | 9.02M |
| 2020 | 0 | -62.35K | 60.54M |
CLRBZ Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 10.61M | 13.31M | 10.06M | 11.44M | 3.85M | 9.42M | 2.41M | 4.67M | -154.67K | 673.73K |
Operating activities | ||||||||||
Net income | -15.09M | -14.09M | -13.23M | -13.56M | -6.18M | -5.49M | -8.05M | -10.78M | -7.43M | -7.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 141.45K | 132.79K | 82.26K | 1.54M | 356.66K | 362.50K | 367.19K | 424.75K | 584.84K | 584.84K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.32M | 907.46K | 907.46K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.32M | 907.46K | 907.46K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 780.60K | 1.12M | -258.79K | 451.32K | 740.50K | -258.06K | -228.11K | 445.10K | -294.96K | -294.96K |
Cash generated by operating activities | 0 | -11.69M | -11.44M | -11.02M | -8.28M | -8.21M | -8.84M | -9.15M | -5.97M | -5.97M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -62.35K | -24.54K | -384.99K | -346.70K | -72.25K | -58.47K | -29.56K | -147.81K | -118.41K | -118.41K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -62.35K | -24.54K | -329.99K | -346.70K | -72.25K | -58.47K | -29.56K | 1.85M | 1.28M | 1.28M |
Financing activities | ||||||||||
Common Stock Issued | 59.71M | 9.02M | 9.07M | 4.90M | 12.32M | 3.3M | 12.39M | 4.97M | 10.16M | 10.16M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -10.61M | -13.25M | -10.00M | -11.44M | -3.85M | -9.42M | 0 | 0 | -5.50M |
Repayments of term debt | 0 | 0 | 0 | 0 | -243.63K | 0 | 0 | 0 | -675.74K | -675.74K |
Cash used in financing activities | 60.54M | 9.02M | 15.02M | 9.92M | 15.94M | 2.70M | 15.87M | 5.04M | 9.51M | 9.51M |
Net Change In Cash | 46.55M | -2.69M | 3.24M | -1.43M | 7.58M | -5.56M | 7.00M | -2.25M | 4.83M | 4.83M |
Cash at end of period | 57.16M | 10.61M | 13.31M | 10.00M | 11.44M | 3.85M | 9.42M | 2.41M | 4.67M | 5.50M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |